Seres Therapeutics, Inc. (MCRB) earnings
MCRB earnings moved a median of -2.93% by the close. Quarterly and annual MCRB reports and results, each read against the price at its own news timestamp. Back to the MCRB overview →
29 measured MCRB earnings events.
Where these MCRB earnings landedvs 29 measured MCRB earnings reactions
| Middle 50% of MCRB earnings reactions | -9.16% to -0.13% |
|---|---|
| Median reaction (to close) | -2.93% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 MCRB earnings events with a measured close landed between -9.16% and -0.13%; 24% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Seres Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.48% | -0.69% | |
| Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs | Press release | -1.95% | -11.10% | |
| Form 10-Q Seres Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.72% | -1.05% | |
| Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | +2.93% | -0.13% | |
| Form 10-K Seres Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | — | +1.34% | |
| Form 10-Q Seres Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.46% | -2.46% | |
| Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | Press release | +1.46% | -7.30% | |
| Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 | Press release | +0.00% | -5.45% | |
| Form 10-Q Seres Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.95% | -6.29% | |
| Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | +0.74% | -2.58% | |
| Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 | Press release | -9.75% | -9.16% | |
| Form 10-Q Seres Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.49% | -2.93% | |
| Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | Press release | -0.82% | -3.04% | |
| Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 | Press release | +17.53% | +33.29% | |
| Form 10-K Seres Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.81% | -0.25% | |
| Form 10-Q Seres Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.12% | -10.70% | |
| Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates | Press release | +1.05% | -9.20% | |
| Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 | Press release | -6.23% | -10.10% | |
| Form 10-Q Seres Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.16% | -7.94% | |
| Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates | Press release | -5.39% | -12.84% | |
| Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024 | Press release | -1.84% | +8.11% | |
| Form 10-Q Seres Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.15% | +0.44% | |
| Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates | Press release | +1.11% | -3.92% | |
| Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024 | Press release | -2.15% | +2.59% | |
| Form 10-K Seres Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.93% | -0.94% | |
| Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024 | Press release | +0.44% | +0.88% | |
| Form 10-Q Seres Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.61% | -28.44% | |
| Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million | Press release | -7.05% | -42.80% | |
| Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST | Press release | -4.03% | +2.69% |
Keep exploring
More MCRB: analyst actions → · SEC filings → · MCRB overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Trinity Biotech plc - American Depositary Shares (TRIB) | 292 | -0.13% | 44% |
| CRISPR Therapeutics AG - Common Shares (CRSP) | 291 | +0.10% | 53% |
| Accuray Incorporated (ARAY) | 288 | 0.00% | 51% |
| Chemed Corp (CHE) | 288 | +0.02% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.